Cyclophosphamide
- Generic Name
- Cyclophosphamide
- Brand Names
- Procytox
- Drug Type
- Small Molecule
- Chemical Formula
- C7H15Cl2N2O2P
- CAS Number
- 50-18-0
- Unique Ingredient Identifier
- 6UXW23996M
- Background
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
- Indication
Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma
- Associated Therapies
- -
NMA Allogeneic Hematopoietic Cell Transplant in Hematologic Cancer/Disorders
- Conditions
- Multiple Myeloma and Plasma Cell NeoplasmMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative DiseasesChronic Myeloproliferative DisordersFanconi AnemiaAplastic AnemiaLeukemiaLymphoma
- Interventions
- Biological: anti-thymocyte globulinBiological: graft-versus-tumor induction therapyBiological: sargramostimBiological: therapeutic allogeneic lymphocytesDrug: cyclophosphamideDrug: fludarabine phosphateDrug: methylprednisoloneDrug: mycophenolate mofetilDrug: tacrolimusProcedure: allogeneic bone marrow transplantationProcedure: peripheral blood stem cell transplantationProcedure: umbilical cord blood transplantation
- First Posted Date
- 2003-02-06
- Last Posted Date
- 2020-02-10
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 41
- Registration Number
- NCT00053989
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Combination Chemotherapy Followed By Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Severe Aplastic Anemia
- Conditions
- LeukemiaMultiple Myeloma and Plasma Cell NeoplasmLymphomaChronic Myeloproliferative DisordersMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative Diseases
- Interventions
- Biological: anti-thymocyte globulinBiological: filgrastimDrug: cyclophosphamideDrug: fludarabine phosphateProcedure: umbilical cord blood transplantationDrug: methylprednisolone
- First Posted Date
- 2003-02-06
- Last Posted Date
- 2020-07-27
- Lead Sponsor
- Case Comprehensive Cancer Center
- Target Recruit Count
- 55
- Registration Number
- NCT00054236
- Locations
- 🇺🇸
Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Combination Chemotherapy Followed By Radiation Therapy in Treating Patients With Aggressive Non-Hodgkin's Lymphoma
- Conditions
- Lymphoma
- Interventions
- Biological: filgrastimDrug: EPOCH regimenDrug: cyclophosphamideDrug: doxorubicin hydrochlorideDrug: etoposideDrug: prednisoneDrug: vincristine sulfateRadiation: radiation therapy
- First Posted Date
- 2003-02-06
- Last Posted Date
- 2021-05-18
- Lead Sponsor
- German High-Grade Non-Hodgkin's Lymphoma Study Group
- Target Recruit Count
- 392
- Registration Number
- NCT00053768
- Locations
- 🇩🇪
Regional Hospital Traunstein, Traunstein, Germany
🇩🇪Hospital Tutzing, Tutzing, Germany
🇩🇪Krankenhaus Der Barmherzigen Brueder, Trier, Germany
Combination Chemotherapy and Antithymocyte Globulin in Reducing Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplantation For Myelodysplastic Syndrome or Myeloproliferative Disorder
- Conditions
- Chronic Myeloproliferative DisordersGraft Versus Host DiseaseLeukemiaMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative Diseases
- First Posted Date
- 2003-02-06
- Last Posted Date
- 2010-05-14
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Registration Number
- NCT00054340
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma
- Conditions
- B-Cell Lymphoma
- Interventions
- First Posted Date
- 2003-02-06
- Last Posted Date
- 2012-09-11
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 50
- Registration Number
- NCT00054665
- Locations
- 🇺🇸
Roswell Parck Cancer Institute, Buffalo, New York, United States
🇺🇸National Cancer Institute (NCI), Bethesda, Maryland, United States
Combination Chemotherapy With or Without Rituximab in Treating Patients With Mantle Cell Lymphoma
- Conditions
- Lymphoma
- First Posted Date
- 2003-01-28
- Last Posted Date
- 2013-12-18
- Lead Sponsor
- Institute of Cancer Research, United Kingdom
- Target Recruit Count
- 82
- Registration Number
- NCT00053092
- Locations
- 🇬🇧
Derriford Hospital, Plymouth, England, United Kingdom
🇦🇺Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
Combination Chemotherapy With or Without Donor Bone Marrow Transplantation in Treating Infants With Previously Untreated Acute Lymphoblastic Leukemia
- Conditions
- Leukemia
- Interventions
- Drug: asparaginaseDrug: cyclophosphamideDrug: cyclosporineDrug: cytarabineDrug: daunorubicin hydrochlorideDrug: dexamethasoneDrug: doxorubicin hydrochlorideDrug: mercaptopurineDrug: methotrexateDrug: methylprednisoloneDrug: pegaspargaseDrug: thioguanineDrug: vincristine sulfateProcedure: allogeneic bone marrow transplantationRadiation: radiation therapy
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2014-02-20
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 6
- Registration Number
- NCT00022126
- Locations
- 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Emory University Hospital - Atlanta, Atlanta, Georgia, United States
🇺🇸Loma Linda University Medical Center, Loma Linda, California, United States
Combination Chemotherapy With or Without Microwave Thermotherapy Before Surgery in Treating Women With Locally Advanced Breast Cancer
- Conditions
- Breast Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-12-19
- Lead Sponsor
- Imunon
- Registration Number
- NCT00036985
- Locations
- 🇺🇸
St. Joseph Hospital Regional Cancer Center - Orange, Orange, California, United States
🇺🇸Mroz-Baier Breast Care Center, Memphis, Tennessee, United States
🇺🇸Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
Combination Chemotherapy in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia
- Conditions
- LeukemiaLymphoma
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-12-19
- Lead Sponsor
- Medical Research Council
- Target Recruit Count
- 120
- Registration Number
- NCT00040690
- Locations
- 🇬🇧
Medical Research Council Clinical Trials Unit, London, England, United Kingdom
Combination Chemotherapy and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia
- Conditions
- Leukemia
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-06-25
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT00002598
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.